AstraZeneca Pharma India Ltd
- P/E
- 89.8x
- 52-week range
- 5,640 – 9,849.5
- ROE
- 23%
- ROCE
- 29%
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; chronic and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →AstraZeneca Pharma India Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)89.8 against a typical 34.6: pricier than most peers (1st = cheapest).187th of 220
- Sales growth+29.8% against a typical +15.6% from a year earlier.58th of 197
- Profit growth−32.1% against a typical +18.9% from a year earlier.123rd of 160
- Share price, 3 months−23.8% against a typical −0.5%.190th of 200
Latest announcements
Exchange filings and their impact on the company.
- Opened a 25,600 sq ft Mumbai corporate office to support commercial growth, with only minor lease and fit-out cost impact.
AstraZeneca Pharma India inaugurated a new 25,600 sq ft corporate office in Mumbai on 16 October 2026, inaugurated by Maharashtra Chief Minister Devendra Fadnavis. The company said it has launched over 25 new medicines and indications in India in three years and is running about 80 global clinical trials, with nearly 5,000 staff in the country. The office strengthens its commercial presence in Mumbai but carries no disclosed sales, capex or hiring target and has only a small cost impact.
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 10 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 26 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 11 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 7 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 14 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 30 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 311 | 306 | 383 | 388 | 408 | 440 | 480 | 526 | 559 | 612 | 579 | 683 |
| Expenses | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 | 484 | 567 | 518 | 634 |
| Operating Profit | 53 | 15 | 49 | 38 | 53 | 77 | 86 | 81 | 75 | 45 | 61 | 49 |
| OPM % | 17% | 4.9% | 13% | 10% | 13% | 17% | 18% | 15% | 13% | 7% | 11% | 7% |
| Other Income | 25 | 10 | 9 | −49 | 8 | −26 | 10 | 11 | 1 | 7 | 5 | 9 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 4 | 4 | 4 | 4 | 9 | 9 | 18 | 17 | 3 | 4 | 6 | 5 |
| Profit before tax | 73 | 20 | 54 | −15 | 51 | 42 | 78 | 75 | 73 | 47 | 58 | 51 |
| Tax % | 29% | 23% | 27% | −22% | 25% | 27% | 26% | 25% | 26% | 30% | 23% | 25% |
| Net Profit | 52 | 16 | 39 | −12 | 38 | 31 | 58 | 56 | 54 | 33 | 45 | 38 |
| EPS in Rs | 20.95 | 6.32 | 15.79 | −4.72 | 15.37 | 12.34 | 23.3 | 22.33 | 21.69 | 13.04 | 17.95 | 15.17 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 15%
- 5 Years
- 23%
- 3 Years
- 31%
- TTM
- 31%
- 10 Years
- 43%
- 5 Years
- 16%
- 3 Years
- 15%
- TTM
- −18%
- 10 Years
- 21%
- 5 Years
- 19%
- 3 Years
- 22%
- TTM
- —
- 10 Years
- 21%
- 5 Years
- 22%
- 3 Years
- 23%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| AstraZeneca Pharma India Ltd | ₹ 6,236.00 | — | 89.8x | — | 23% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 36.6x | 5.3x | 0% | 0% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 94.3x | 14.8x | 0% | 0% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 75.8x | 20x | 0% | 0% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.7x | 4.2x | 0% | 0% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 26.6x | 3.2x | 0% | 0% |
Management
- Tanya Sanish
- Compliance Officer, Company Secretary
- Praveen Rao Akkinepally
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.